Results for haemoglobinopathies translation from English to Croatian

haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).
hemoglobinopatije (npr. talasemija, anemija srpastih stanica).

the safety and efficacy of mircera therapy has not been established in patients with haemoglobinopathies, seizures, bleeding or a recent history of bleeding requiring transfusions or with platelet levels greater than 500 x 109/l.
sigurnost i djelotvornost terapije lijekom mircera nije utvrđena u bolesnika s hemoglobinopatijama, neurološkim napadajima, krvarenjem ili nedavnim krvarenjem koja su zahtijevala transfuziju ili uz razinu trombocita veću od 500 x 109/l.

it is not known if mircera has a different effect in patients with haemoglobinopathies (disorders associated with abnormal haemoglobin), past or present bleeding, seizures or with a high blood platelet count.
nije poznato ima li mircera drukčiji učinak na bolesnike s hemoglobinopatijama (poremećaji povezani s abnormalnim hemoglobinom), prisutnim krvarenjem ili krvarenjem u prošlosti, neurološkim napadima ili povišenim brojem trombocita u krvi.

in the majority of patients with urea cycle disorders or haemoglobinopathies receiving various doses of phenylbutyrate (300 - 650 mg/kg/day up to 20 g/day) no plasma level of phenylacetate could be detected after overnight fasting.
u većine bolesnika s poremećajem ciklusa ureje ili hemoglobinopatijom koji su primali različite doze fenilbutirata (300 – 650 mg/kg/dan do 20 g/dan) nakon noćnog posta nije otkrivena prisutnost fenilacetata u plazmi.